Results 101 to 110 of about 554 (134)
Some of the next articles are maybe not open access.
Caproate formation in mixed-culture fermentative hydrogen production
Bioresource Technology, 2010Caproate always appears during fermentative H(2) production but its formation was not well explained. It possibly results from the secondary fermentation of ethanol and acetate or butyrate by some special species like Clostridium kluyveri. This study attempts to elucidate caproate formation during the fermentation H(2) production by using C.
Hong-Bo, Ding +2 more
openaire +2 more sources
17-alpha-hydroprogesterone caproate and cervical changes
American Journal of Obstetrics and Gynecology, 2010ObjectiveThe purpose of this study was to evaluate whether 17-a-hydroxyprogesterone caproate (17P) treatment affect changes in cervical length.Study DesignWomen with singleton pregnancy, between 25 and 33 + 6 weeks of gestation, who were hospitalized for preterm labor were included.
openaire +2 more sources
Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate
American Journal of Obstetrics and Gynecology, 2007This study was undertaken to assess the impact of 17 alpha hydroxyprogesterone caproate treatment on future medical costs for expectant mothers with a prior spontaneous preterm birth.Data on the costs of preterm birth were combined with published data on the effectiveness of 17 alpha hydroxyprogesterone caproate to produce estimates of the effect of ...
Jennifer L, Bailit, Mark E, Votruba
openaire +2 more sources
Human placental transfer of 17-hyrdoxyprogesterone caproate
American Journal of Obstetrics and Gynecology, 2006SARAH HEMAUER, SVETLANA PATRIKEEVA, GARY HANKINS, MAHMOUD AHMED, TATIANA NANOVSKAYA, University of Texas Medical Branch at Galveston, Obstetrics and Gynecology, Galveston, Texas OBJECTIVE: 17a-hydroxyprogesterone caproate (17HPC) results in 30% reduction in the rate of recurrent preterm deliveries.
Sarah Hemauer +4 more
openaire +1 more source
17 α-Hydroxyprogesterone Caproate (Makena™)
Pediatric Drugs, 201117 α-hydroxyprogesterone caproate is a synthetic progestin of which there is now a US FDA-approved formulation available for intramuscular administration (Makena™) to reduce the risk of preterm birth. Intramuscular 17 α-hydroxyprogesterone caproate (identical in formulation and manufacturing process to Makena™, thus hereafter referred to as Makena ...
openaire +2 more sources
Compounded hydroxyprogesterone caproate
American Journal of Obstetrics and Gynecology, 2013John L, Chollet +2 more
openaire +2 more sources
17 alpha-hydroxyprogesterone caproate, HIV, and preterm birth
The Lancet HIV, 2021Robert, Ntozini, Andrew J, Prendergast
openaire +2 more sources
Immune effects of 17α-hydroxyprogesterone caproate
American Journal of Obstetrics and Gynecology, 2022openaire +2 more sources